JP2022542472A - 抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法 - Google Patents

抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法 Download PDF

Info

Publication number
JP2022542472A
JP2022542472A JP2022506612A JP2022506612A JP2022542472A JP 2022542472 A JP2022542472 A JP 2022542472A JP 2022506612 A JP2022506612 A JP 2022506612A JP 2022506612 A JP2022506612 A JP 2022506612A JP 2022542472 A JP2022542472 A JP 2022542472A
Authority
JP
Japan
Prior art keywords
individual
seq
amino acid
dose
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542472A5 (enExample
Inventor
ブピンダー シン，
ヘンリク ラスムッセン，
Original Assignee
アラコス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラコス インコーポレイテッド filed Critical アラコス インコーポレイテッド
Publication of JP2022542472A publication Critical patent/JP2022542472A/ja
Publication of JP2022542472A5 publication Critical patent/JP2022542472A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
JP2022506612A 2019-08-02 2020-07-31 抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法 Pending JP2022542472A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882330P 2019-08-02 2019-08-02
US62/882,330 2019-08-02
PCT/US2020/044583 WO2021026021A1 (en) 2019-08-02 2020-07-31 Methods of administering anti-siglec-8 antibodies and corticosteroids

Publications (2)

Publication Number Publication Date
JP2022542472A true JP2022542472A (ja) 2022-10-03
JP2022542472A5 JP2022542472A5 (enExample) 2023-07-31

Family

ID=74504001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506612A Pending JP2022542472A (ja) 2019-08-02 2020-07-31 抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法

Country Status (11)

Country Link
US (1) US20220257758A1 (enExample)
EP (1) EP4007606A4 (enExample)
JP (1) JP2022542472A (enExample)
KR (1) KR20220044203A (enExample)
CN (1) CN114466664A (enExample)
AU (1) AU2020325097A1 (enExample)
BR (1) BR112022001395A2 (enExample)
CA (1) CA3149484A1 (enExample)
IL (1) IL290111A (enExample)
MX (1) MX2022001403A (enExample)
WO (1) WO2021026021A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019013136A (es) * 2017-05-05 2020-07-14 Allakos Inc Metodos y composiciones para tratar trastornos gastrointestinales inflamatorios.
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
WO2024043940A1 (en) * 2022-08-25 2024-02-29 Allakos Inc. Methods and compositions for treating atopic dermatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129400A1 (en) * 2017-01-06 2018-07-12 Allakos Inc. Methods and compositions for treating chronic obstructive pulmonary disorder
WO2018204868A1 (en) * 2017-05-05 2018-11-08 Allakos Inc. Methods and compositions for treating allergic ocular diseases
WO2018204871A1 (en) * 2017-05-05 2018-11-08 Allakos Inc. Methods and compositions for treating inflammatory gastrointestinal disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210125114A (ko) * 2013-12-09 2021-10-15 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129400A1 (en) * 2017-01-06 2018-07-12 Allakos Inc. Methods and compositions for treating chronic obstructive pulmonary disorder
WO2018204868A1 (en) * 2017-05-05 2018-11-08 Allakos Inc. Methods and compositions for treating allergic ocular diseases
WO2018204871A1 (en) * 2017-05-05 2018-11-08 Allakos Inc. Methods and compositions for treating inflammatory gastrointestinal disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 128, no. 22, JPN6024020945, 2016, pages 1149, ISSN: 0005487401 *
CANCER, vol. 116, JPN6024020946, 2010, pages 1827 - 1837, ISSN: 0005487400 *
THE ONCOLOGIST, vol. 13, JPN6024020947, 2008, pages 725 - 732, ISSN: 0005487399 *

Also Published As

Publication number Publication date
CN114466664A (zh) 2022-05-10
EP4007606A4 (en) 2023-09-27
CA3149484A1 (en) 2021-02-11
WO2021026021A1 (en) 2021-02-11
MX2022001403A (es) 2022-03-25
KR20220044203A (ko) 2022-04-06
BR112022001395A2 (pt) 2022-06-07
EP4007606A1 (en) 2022-06-08
AU2020325097A1 (en) 2022-03-03
IL290111A (en) 2022-03-01
US20220257758A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP7346304B2 (ja) 炎症性消化器障害を処置するための方法および組成物
US20220135673A1 (en) Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
JP2023086917A (ja) アレルギー性眼疾患を処置するための方法および組成物
US20230406920A1 (en) Anti-siglec-8 antibody formulations
US20220257758A1 (en) Methods of administering anti-siglec-8 antibodies and corticosteroids
JP2024534429A (ja) 抗ｓｉｇｌｅｃ－６抗体およびその使用方法
JP2024045612A (ja) 慢性蕁麻疹を処置するための方法および組成物
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
JP2022553378A (ja) 過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物
WO2024043940A1 (en) Methods and compositions for treating atopic dermatitis
EA046789B1 (ru) Способы и композиции для лечения воспалительных расстройств желудочно-кишечного тракта

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241218